June 29, 2022 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces $2.975 Billion Fund XII to Create and Fund Early Stage Biotechnology Companies
June 7, 2022 Press Releases from ARCH Venture Partners | Share ARCH Venture Partners Announces Promotions and New Appointment
May 19, 2022 Portfolio News from ARCH Venture Partners | Share Bob Nelsen-founded Resilience inks manufacturing pact with ARCH-backed Be Bio
May 16, 2022 Media Coverage from ARCH Venture Partners | Share John Maraganore named on Fierce’s Most Influential People in BioPharma list
May 9, 2022 Media Coverage from ARCH Venture Partners | Share John Maraganore’s “Reflections on Alnylam,” published in Nature Biotech
April 26, 2022 Portfolio News from ARCH Venture Partners | Share Irv Weissman’s lab spins out Pheast Therapeutics to target new ‘don’t eat me’ signal, $76M Series A led by ARCH Venture
April 14, 2022 Portfolio News from ARCH Venture Partners | Share ARCH leads $130M infusion into Be Bio’s long pursuit of B cell therapies for rare disease, cancer
March 14, 2022 Portfolio News from ARCH Venture Partners | Share Nutcracker Therapeutics with Bob Nelsen backing lands $167M to develop its own cancer drugs
March 9, 2022 Portfolio News from ARCH Venture Partners | Share Exclusive: ARCH and GV are building a large startup focused on mitochondrial diseases
February 24, 2022 Portfolio News from ARCH Venture Partners | Share With a new startup, ARCH and Takeda wade into growing search for a Swiss Army knife RNA drug
February 22, 2022 Media Coverage from ARCH Venture Partners | Share Bob Nelsen makes the STAT News 2022 STATUS list. Multiple founders and leaders of ARCH portfolio companies also named, including Jennifer Doudna, Yvonne Greenstreet, Leroy Hood, Daphne Koller and David Liu.
January 20, 2022 Portfolio News from ARCH Venture Partners | Share Super-resolution microscope maker ONI nabs $75M for US expansion, Series B led by ARCH Venture
